{"api":"v1","generated_at":"2026-10-01T10:19:46.711Z","licence":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"TOLL, with a link to the page cited"},"page":"https://tollindex.com/e/api-magentlab-com-api-calc-mrecist-a480f6","pinned_page":"https://tollindex.com/e/api-magentlab-com-api-calc-mrecist-a480f6/at/2026-10-01T05-50Z","pinned":false,"method":"https://tollindex.com/ledger/method","snapshot_at":"2026-10-01T05:50:06.230Z","snapshot_stamp":"2026-10-01T05-50Z","endpoint":{"slug":"api-magentlab-com-api-calc-mrecist-a480f6","canonical_url":"https://api.magentlab.com/api/calc/mrecist","resource":"https://api.magentlab.com/api/calc/mrecist","http_method":"POST","type":"http","x402_version":2,"registries":["cdp"],"primary_registry":"cdp","curated_by_coinbase":false,"description":"Lencioni 2010 mRECIST for typical intrahepatic HCC target lesions. First-match: PD if new_lesion or a 20% or greater viable-sum increase vs nadir; else CR if arterial enhancement disappeared in all targets; else PR if a 30% or greater viable-sum decrease vs baseline; else SD. Caller-assigned flags; magent does not read imaging. Not a medical device, not a diagnosis, not RECIST 1.1, not EASL necrosis-only, not the 2019 Llovet +5 mm PD refinement, and not nontarget-only overall response.","service_name":"magent","declared_category":null,"declared_tags":["mrecist","hcc","liver","response","calculator"],"route_template":null,"registry_updated":"2026-09-28T14:06:00.320Z"},"derived":{"note":"fields no registry supplies; TOLL derives them and marks them derived on the page","title":"calc mrecist","category":"other","first_observed_by_toll":"2026-09-28T13:51:25.436Z","last_observed_by_toll":"2026-10-01T05:50:06.230Z","observation_began":"2026-09-10"},"presence":{"listed_now":true,"first_absent_at":null,"delisting_confirmed_at":null,"events":[{"registry":"cdp","at":"2026-09-28T13:51:25.437Z","event":"listed"}]},"accepts":[{"registry":"cdp","ordinal":0,"network":"eip155:8453","asset":"0x833589fcd6edb6e08f4c7c32d4f71b54bda02913","asset_name":"USD Coin","symbol":"USDC","decimals":6,"amount_display":"0.005 USDC","amount_units":0.005,"decimals_known":true,"pay_to":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","scheme":"exact"}],"counters":{"observed_at":"2026-10-01T05:50:06.230Z","calls_30d":2,"unique_payers_30d":1,"last_called_at":"2026-09-28T14:06:00.121Z"},"validation":{"latest":{"observed_at":"2026-10-01T08:48:29.178Z","state":"pass","failed_checks":[],"endpoint_http_status":402,"run_id":"daily-2026-10-01"},"uptime":[{"days":7,"observed":5,"passed":5,"ratio":1},{"days":30,"observed":5,"passed":5,"ratio":1},{"days":90,"observed":5,"passed":5,"ratio":1}],"history_90d":[{"observed_at":"2026-10-01T08:48:29.178Z","state":"pass","failed_checks":[],"run_id":"daily-2026-10-01","state_changed":false},{"observed_at":"2026-09-30T08:12:38.553Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-30","state_changed":false},{"observed_at":"2026-09-29T20:22:41.898Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-29","state_changed":false},{"observed_at":"2026-09-28T17:30:12.510Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-28","state_changed":false},{"observed_at":"2026-09-28T16:46:24.993Z","state":"pass","failed_checks":[],"run_id":"new-after-daily-2026-09-28","state_changed":true}]},"seller":{"wallet":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","page":"https://tollindex.com/seller/0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","endpoints":844,"hosts":1},"reports":0,"registry_record":{"cdp":[{"tags":["mrecist","hcc","liver","response","calculator"],"type":"http","accepts":[{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2","paymentFlow":"upfront","resourceUrl":"https://api.magentlab.com/api/calc/mrecist","assetTransferMethod":"eip3009"},"payTo":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","amount":"5000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":600}],"quality":{"lastCalledAt":"2026-09-28T14:06:00.121Z","l30DaysTotalCalls":2,"l30DaysUniquePayers":1},"resource":"https://api.magentlab.com/api/calc/mrecist","extensions":{"bazaar":{"info":{"input":{"body":{"items":[{"new_lesion":false,"enhancement_disappeared":true,"viable_sum_increase_ge_20":false,"viable_sum_reduction_ge_30":false},{"new_lesion":false,"enhancement_disappeared":true,"viable_sum_increase_ge_20":false,"viable_sum_reduction_ge_30":false}]},"type":"http","method":"POST"},"output":{"type":"json","example":{"path":"/api/calc/mrecist","count":2,"items":[{"formula":"mrecist","mrecist":"CR","citation":{"id":"lencioni-2010","doi":"10.1055/s-0030-1247132","pmid":"20175033","title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","source":"Semin Liver Dis. 2010;30(1):52-60","authors":"Lencioni R, Llovet JM"},"criteria":[{"met":false,"factor":"new_lesion"},{"met":false,"factor":"viable_sum_increase_ge_20"},{"met":true,"factor":"enhancement_disappeared"},{"met":false,"factor":"viable_sum_reduction_ge_30"}],"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","formula_expression":"mrecist first-match: PD if new_lesion or viable_sum_increase_ge_20; else CR if enhancement_disappeared; else PR if viable_sum_reduction_ge_30; else SD (Lencioni 2010 typical intrahepatic target lesions). Not RECIST 1.1. Not EASL necrosis-only. Not the 2019 Llovet +5 mm PD refinement. magent does not read imaging. Not a diagnosis"},{"formula":"mrecist","mrecist":"CR","citation":{"id":"lencioni-2010","doi":"10.1055/s-0030-1247132","pmid":"20175033","title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","source":"Semin Liver Dis. 2010;30(1):52-60","authors":"Lencioni R, Llovet JM"},"criteria":[{"met":false,"factor":"new_lesion"},{"met":false,"factor":"viable_sum_increase_ge_20"},{"met":true,"factor":"enhancement_disappeared"},{"met":false,"factor":"viable_sum_reduction_ge_30"}],"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","formula_expression":"mrecist first-match: PD if new_lesion or viable_sum_increase_ge_20; else CR if enhancement_disappeared; else PR if viable_sum_reduction_ge_30; else SD (Lencioni 2010 typical intrahepatic target lesions). Not RECIST 1.1. Not EASL necrosis-only. Not the 2019 Llovet +5 mm PD refinement. magent does not read imaging. Not a diagnosis"}]}},"iconUrl":"https://api.magentlab.com/favicon.ico"},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"body":{"type":"object","required":["items"],"properties":{"items":{"type":"array","items":{"type":"object","required":["new_lesion","viable_sum_increase_ge_20","enhancement_disappeared","viable_sum_reduction_ge_30"],"properties":{"new_lesion":{"type":"boolean","description":"One or more new lesions as assigned by the caller (Lencioni 2010 mRECIST PD). true or false. When true, mrecist is PD regardless of enhancement or viable-sum flags. magent does not read imaging."},"enhancement_disappeared":{"type":"boolean","description":"Disappearance of any intratumoral arterial enhancement in all target lesions, as assigned by the caller (Lencioni 2010 mRECIST CR). true or false. magent does not measure arterial-phase enhancement or read CT/MRI."},"viable_sum_increase_ge_20":{"type":"boolean","description":"≥20% increase in the sum of diameters of viable (arterial-enhancing) target lesions versus nadir, as assigned by the caller (Lencioni 2010 mRECIST PD). Do not also require a 5 mm absolute increase. true or false. magent does not measure lesions."},"viable_sum_reduction_ge_30":{"type":"boolean","description":"≥30% decrease in the sum of diameters of viable (arterial-enhancing) target lesions versus baseline, as assigned by the caller (Lencioni 2010 mRECIST PR). true or false. magent does not measure lesions."}}},"maxItems":25,"minItems":1}},"additionalProperties":false},"type":{"type":"string","const":"http"},"method":{"type":"string","const":"POST"},"headers":{"type":"object","additionalProperties":{"type":"string"}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}}}},"description":"Lencioni 2010 mRECIST for typical intrahepatic HCC target lesions. First-match: PD if new_lesion or a 20% or greater viable-sum increase vs nadir; else CR if arterial enhancement disappeared in all targets; else PR if a 30% or greater viable-sum decrease vs baseline; else SD. Caller-assigned flags; magent does not read imaging. Not a medical device, not a diagnosis, not RECIST 1.1, not EASL necrosis-only, not the 2019 Llovet +5 mm PD refinement, and not nontarget-only overall response.","lastUpdated":"2026-09-28T14:06:00.32Z","serviceName":"magent","x402Version":2}]}}